Suggestions

Du même auteur

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Archive ouverte | Peters, S. | CCSD

International audience

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

Archive ouverte | Borget, I. | CCSD

International audience. Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not...

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Archive ouverte | Molinier, O. | CCSD

International audience. Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) is currently the standard of care in patients ...

Chargement des enrichissements...